Positive Clinical Data For PBI-1402 Presented At The Annual Congress Of The European Hematology Association

ProMetic Life Sciences Inc. (TSX:PLI) (”ProMetic”) presented results on its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia (”CIA”) at the 13th Congress of the European Hematology Association held in Copenhagen, Denmark this week.Dr. Lyne Gagnon, ProMetic’s Director R&D, Biology, presented data on PBI-1402 in a poster entitled “PBI-1402 increases hemoglobin level and red blood cell count in chemotherapy-induced anemia”.

More: continued here

Filed under: Blood on June 19th, 2008